Crossmark

Outcomes of endoscopic submucosal dissection for gastroesophageal reflux disease (ESD-G) for medication-refractory gastroesophageal reflux disease: 35 cases underwent ESD-G including 15 cases followed more than 5 years

Crossref DOI link: https://doi.org/10.1186/s12876-021-02022-x

Published Online: 2021-11-18

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ota, Kazuhiro

Takeuchi, Toshihisa

Kojima, Yuichi

Sugawara, Noriaki

Nishida, Shinya

Iwatsubo, Taro

Kawaguchi, Shimpei

Harada, Satoshi

Tokioka, Satoshi

Higuchi, Kazuhide
License Information

Text and Data Mining valid from 2021-11-18

Version of Record valid from 2021-11-18
More Information

Article History

Received: 29 May 2021

Accepted: 9 November 2021

First Online: 18 November 2021

Declarations

:

: The present study was a single-center, single-arm trial conducted at the Osaka Medical and Pharmaceutical University Hospital. The study was conducted in accordance with the 1975 Declaration of Helsinki (as revised in 1983). The protocol was approved by the ethics review committee at Osaka Medical and Pharmaceutical University (No. 0563, May 12, 2008 and No. 1507, March 3, 2016) and registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN000042538). We informed consent was obtained from all the participants.

: Not applicable.

: The authors have no conflict of interest to declare.

Document is current

Any future updates will be listed below